[{"id":"7804b598-a4ee-4247-b0fd-55fd2504d527","acronym":"","url":"https://clinicaltrials.gov/study/NCT02035813","created_at":"2021-01-18T09:20:22.799Z","updated_at":"2024-07-02T16:34:58.978Z","phase":"Phase 2","brief_title":"DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).","source_id_and_acronym":"NCT02035813","lead_sponsor":"Prof. Wolfgang Janni","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HR negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HR negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 116","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 01/10/2024","primary_completion_date":" 01/10/2024","study_txt":" Completion: 01/10/2024","study_completion_date":" 01/10/2024","last_update_posted":"2024-06-04"},{"id":"dc735828-f429-4451-8fe7-87ae461e63ae","acronym":"NRG-BR005","url":"https://clinicaltrials.gov/study/NCT03188393","created_at":"2021-01-18T15:43:14.938Z","updated_at":"2024-07-02T16:35:00.129Z","phase":"Phase 2","brief_title":"Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery","source_id_and_acronym":"NCT03188393 - NRG-BR005","lead_sponsor":"NRG Oncology","biomarkers":" PD-L1 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR negative","tags":["PD-L1 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR negative"],"overall_status":"Suspended","enrollment":" Enrollment 175","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 07/05/2019","primary_completion_date":" 07/05/2019","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-30"},{"id":"c0f6572e-e0b9-41ba-be48-0dac251b1d1a","acronym":"A011801","url":"https://clinicaltrials.gov/study/NCT04457596","created_at":"2021-01-18T21:26:12.793Z","updated_at":"2024-07-02T16:35:01.275Z","phase":"Phase 3","brief_title":"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","source_id_and_acronym":"NCT04457596 - A011801","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HR negative • ER negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HR negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 1031","initiation":"Initiation: 01/06/2021","start_date":" 01/06/2021","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 05/01/2035","study_completion_date":" 05/01/2035","last_update_posted":"2024-05-23"},{"id":"bf174275-025d-484c-93f9-5e3ccfbe6e13","acronym":"","url":"https://clinicaltrials.gov/study/NCT01827787","created_at":"2021-01-18T08:07:25.626Z","updated_at":"2024-07-02T16:35:03.572Z","phase":"Phase 2","brief_title":"Eribulin in HER2 Negative Metastatic BrCa","source_id_and_acronym":"NCT01827787","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 83","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2024-05-15"},{"id":"86fab96d-2e9b-46db-bfb5-1b9bf74ce73a","acronym":"AIPAC-003","url":"https://clinicaltrials.gov/study/NCT05747794","created_at":"2023-02-28T13:01:27.736Z","updated_at":"2024-07-02T16:35:04.109Z","phase":"Phase 2/3","brief_title":"Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy","source_id_and_acronym":"NCT05747794 - AIPAC-003","lead_sponsor":"Immutep S.A.S.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HR negative • PGR positive","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HR negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ImmuFact (eftilagimod alpha)"],"overall_status":"Recruiting","enrollment":" Enrollment 849","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-05-13"},{"id":"55778a5f-c686-4687-a67d-c14a84d3bdda","acronym":"PERGIQUAL","url":"https://clinicaltrials.gov/study/NCT05893368","created_at":"2023-06-07T14:08:08.998Z","updated_at":"2024-07-02T16:35:07.854Z","phase":"","brief_title":"New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer","source_id_and_acronym":"NCT05893368 - PERGIQUAL","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative • HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HR negative"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-04-24"},{"id":"a807a23b-d916-49a5-bf5d-9adada61ab5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05861271","created_at":"2023-05-16T17:06:46.295Z","updated_at":"2024-07-02T16:35:13.295Z","phase":"Phase 2","brief_title":"Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer","source_id_and_acronym":"NCT05861271","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HR negative • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HR negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • capecitabine • Irene (pyrotinib) • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 1008","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-03-22"},{"id":"2edf3b16-165f-4c9f-b544-911f427ca536","acronym":"A-Brave","url":"https://clinicaltrials.gov/study/NCT02926196","created_at":"2021-01-18T14:22:23.709Z","updated_at":"2024-07-02T16:35:13.466Z","phase":"Phase 3","brief_title":"Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab","source_id_and_acronym":"NCT02926196 - A-Brave","lead_sponsor":"Istituto Oncologico Veneto IRCCS","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression • HER-2 amplification • HER-2 negative • HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 amplification • HER-2 negative • HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 474","initiation":"Initiation: 06/17/2016","start_date":" 06/17/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-03-21"},{"id":"fa0a16d9-bc9f-4cf1-a454-6909e3b1d1b2","acronym":"TavIx","url":"https://clinicaltrials.gov/study/NCT00630032","created_at":"2021-01-18T02:20:34.220Z","updated_at":"2024-07-02T16:35:18.454Z","phase":"Phase 3","brief_title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","source_id_and_acronym":"NCT00630032 - TavIx","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • HR negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HR negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • 5-fluorouracil • cyclophosphamide • epirubicin • Ixempra (ixabepilone)"],"overall_status":"Completed","enrollment":" Enrollment 762","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 09/03/2020","study_completion_date":" 09/03/2020","last_update_posted":"2024-02-21"},{"id":"9ae1ceef-9050-4e49-a2ad-14c940da296c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05266937","created_at":"2022-03-04T15:53:28.377Z","updated_at":"2024-07-02T16:35:21.272Z","phase":"Phase 2","brief_title":"Atezolizumab Plus CArboplatin Plus Nab-paclitaxel","source_id_and_acronym":"NCT05266937","lead_sponsor":"Consorzio Oncotech","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • HR negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 07/03/2020","start_date":" 07/03/2020","primary_txt":" Primary completion: 07/03/2024","primary_completion_date":" 07/03/2024","study_txt":" Completion: 07/03/2024","study_completion_date":" 07/03/2024","last_update_posted":"2024-02-01"},{"id":"ad913eea-8274-4eb1-8681-7cc3534570b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04803084","created_at":"2021-03-17T15:57:44.924Z","updated_at":"2024-07-02T16:35:26.485Z","phase":"","brief_title":"Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment","source_id_and_acronym":"NCT04803084","lead_sponsor":"Laura Kennedy","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • HR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HR negative"],"overall_status":"Suspended","enrollment":" Enrollment 10","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-12-12"},{"id":"b01abc76-a9b1-4a0e-8d3d-7c94aad01cf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02804815","created_at":"2021-01-18T13:45:12.829Z","updated_at":"2024-07-02T16:35:27.565Z","phase":"Phase 3","brief_title":"Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours","source_id_and_acronym":"NCT02804815","lead_sponsor":"University College, London","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 11000","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-11-30"},{"id":"c281a94f-ba0b-4b22-9966-de04e9d676d7","acronym":"TUXEDO-2","url":"https://clinicaltrials.gov/study/NCT05866432","created_at":"2023-05-19T13:04:50.730Z","updated_at":"2024-07-02T16:35:32.586Z","phase":"Phase 2","brief_title":"Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases","source_id_and_acronym":"NCT05866432 - TUXEDO-2","lead_sponsor":"Medical University of Vienna","biomarkers":" PD-L1","pipe":" | ","alterations":" HR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 05/23/2026","primary_completion_date":" 05/23/2026","study_txt":" Completion: 05/23/2026","study_completion_date":" 05/23/2026","last_update_posted":"2023-10-19"},{"id":"b83f7b71-9d99-4ff1-9bd9-0adc4d40be51","acronym":"IUCRO-0154","url":"https://clinicaltrials.gov/study/NCT00577122","created_at":"2021-01-18T02:06:38.965Z","updated_at":"2024-07-02T16:35:33.440Z","phase":"Phase 2","brief_title":"Medroxyprogesterone +/- Cyclophosphamide \u0026 Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer","source_id_and_acronym":"NCT00577122 - IUCRO-0154","lead_sponsor":"Indiana University","biomarkers":" ER • PGR","pipe":" | ","alterations":" HR negative • ER negative • PGR negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2007","start_date":" 07/01/2007","primary_txt":" Primary completion: 12/01/2011","primary_completion_date":" 12/01/2011","study_txt":" Completion: 12/01/2011","study_completion_date":" 12/01/2011","last_update_posted":"2023-10-16"},{"id":"0a8b544d-5385-4b08-8266-87f1c34ba6c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04020185","created_at":"2021-01-18T19:44:10.860Z","updated_at":"2024-07-02T16:35:33.960Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of IMSA101 in Refractory Malignancies","source_id_and_acronym":"NCT04020185","lead_sponsor":"ImmuneSensor Therapeutics Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" HR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMSA101"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/23/2019","start_date":" 09/23/2019","primary_txt":" Primary completion: 09/15/2023","primary_completion_date":" 09/15/2023","study_txt":" Completion: 09/15/2023","study_completion_date":" 09/15/2023","last_update_posted":"2023-10-11"},{"id":"c6f9cbc2-76fa-4211-9fb0-5b14aa0568d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04020575","created_at":"2021-01-18T19:44:34.590Z","updated_at":"2024-07-02T16:35:45.435Z","phase":"Phase 1","brief_title":"Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)","source_id_and_acronym":"NCT04020575","lead_sponsor":"Minerva Biotechnologies Corporation","biomarkers":" HER-2 • PGR • MUC1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative","tags":["HER-2 • PGR • MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huMNC2-CAR22 • huMNC2-CAR44 CAR T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/15/2035","study_completion_date":" 01/15/2035","last_update_posted":"2023-06-16"},{"id":"8b86144c-5724-45bb-a024-35b77692ac4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02236000","created_at":"2021-01-17T17:38:14.672Z","updated_at":"2024-07-02T16:35:57.015Z","phase":"Phase 1/2","brief_title":"A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer","source_id_and_acronym":"NCT02236000","lead_sponsor":"NSABP Foundation Inc","biomarkers":" ER • PGR","pipe":" | ","alterations":" HR positive • HR negative • EGFR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HR negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2023-01-26"},{"id":"c1296de0-c844-4682-8a71-07ca7ed702b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01008150","created_at":"2021-01-18T03:56:36.499Z","updated_at":"2024-07-02T16:36:22.518Z","phase":"Phase 2","brief_title":"Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer","source_id_and_acronym":"NCT01008150","lead_sponsor":"NSABP Foundation Inc","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Nerlynx (neratinib) • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 11/25/2016","study_completion_date":" 11/25/2016","last_update_posted":"2021-10-25"},{"id":"4bc47ddd-2a6a-4934-a607-63c23f0ed11b","acronym":"CAREGIVER","url":"https://clinicaltrials.gov/study/NCT05067530","created_at":"2021-10-05T20:00:09.678Z","updated_at":"2024-07-02T16:36:23.516Z","phase":"Phase 2","brief_title":"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study","source_id_and_acronym":"NCT05067530 - CAREGIVER","lead_sponsor":"Medical University of Gdansk","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative • HR negative • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HR negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • carboplatin • paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/06/2026","study_completion_date":" 12/06/2026","last_update_posted":"2021-10-05"},{"id":"08eacf90-f860-42e0-8a30-4b21625379a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04437160","created_at":"2021-01-18T21:21:40.977Z","updated_at":"2024-07-02T16:36:43.993Z","phase":"Phase 2","brief_title":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","source_id_and_acronym":"NCT04437160","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • epirubicin • Pinorubin (pirarubicin) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 286","initiation":"Initiation: 02/01/2020","start_date":" 02/01/2020","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2020-06-19"},{"id":"b93c6f34-7a2c-4a53-ac7b-1405bff52493","acronym":"","url":"https://clinicaltrials.gov/study/NCT01216111","created_at":"2021-01-18T04:52:54.168Z","updated_at":"2024-07-02T16:36:44.939Z","phase":"Phase 3","brief_title":"Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)","source_id_and_acronym":"NCT01216111","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • BRCA1 • HRD","pipe":" | ","alterations":" BRCA1 mutation • HER-2 negative • HR negative","tags":["HER-2 • PGR • BRCA1 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HER-2 negative • HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 647","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 04/20/2016","primary_completion_date":" 04/20/2016","study_txt":" Completion: 04/20/2016","study_completion_date":" 04/20/2016","last_update_posted":"2020-05-19"},{"id":"cf991d7b-da8c-4507-97f4-97f2a03cdabc","acronym":"","url":"https://clinicaltrials.gov/study/NCT00445887","created_at":"2021-01-18T01:34:34.432Z","updated_at":"2024-07-02T16:36:53.457Z","phase":"Phase 2","brief_title":"Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer","source_id_and_acronym":"NCT00445887","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" ER • PGR • BRCA1 • BRCA2 • TGFB1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HR negative • ER negative • PGR negative","tags":["ER • PGR • BRCA1 • BRCA2 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HR negative • ER negative • PGR negative"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/10/2008","start_date":" 03/10/2008","primary_txt":" Primary completion: 12/11/2013","primary_completion_date":" 12/11/2013","study_txt":"","study_completion_date":"","last_update_posted":"2019-11-19"},{"id":"a785860c-de33-4ed3-84fc-dc128913acad","acronym":"IMPACt","url":"https://clinicaltrials.gov/study/NCT02670577","created_at":"2021-01-18T13:01:10.099Z","updated_at":"2024-07-02T16:37:09.423Z","phase":"","brief_title":"Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry","source_id_and_acronym":"NCT02670577 - IMPACt","lead_sponsor":"Agendia","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 amplification • HER-2 negative • HR negative • ER positive + PGR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 amplification • HER-2 negative • HR negative • ER positive + PGR positive"],"overall_status":"Completed","enrollment":" Enrollment 481","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 04/30/2017","primary_completion_date":" 04/30/2017","study_txt":" Completion: 08/01/2017","study_completion_date":" 08/01/2017","last_update_posted":"2018-06-27"},{"id":"754bd7c0-262b-42ae-873c-8545c929aa1f","acronym":"READ","url":"https://clinicaltrials.gov/study/NCT00689156","created_at":"2021-01-18T02:34:35.273Z","updated_at":"2024-07-02T16:37:11.731Z","phase":"Phase 3","brief_title":"Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer","source_id_and_acronym":"NCT00689156 - READ","lead_sponsor":"Danish Breast Cancer Cooperative Group","biomarkers":" HER-2 • PGR • TOP2A","pipe":" | ","alterations":" HER-2 positive • HR positive • HR negative • PGR negative","tags":["HER-2 • PGR • TOP2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HR negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 2015","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 01/01/2013","study_completion_date":" 01/01/2013","last_update_posted":"2018-04-05"}]